News

The ALS Society of Canada (ALS Canada) is proud to once again partner with Mitsubishi Tanabe Pharma Canada to support promising advancements in ALS care through the 2024 Mitsubishi Tanabe Pharma Canada Fellowship. This fellowship funds individuals dedicated to improving clinical care for people…

This series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario, these…

ALS researchers worldwide continue to build upon existing work and make new discoveries in the hopes of realizing a world free of ALS. In the January 2025 Research Update, explore new insights into predicting disease onset, new potential therapies and…

Canada’s Drug Agency (CDA), formerly known as the Canadian Agency for Drugs and Technologies in Health (CADTH), has posted a call for patient input on tofersen, a therapy currently under review by Health Canada. This is an important opportunity for…

From December 2 to 8, 2024, the ALS Society of Canada (ALS Canada) and the ALS Society of Quebec (ALS Quebec) co-hosted a series of events that brought more than 1,500 delegates from around the world to Montreal to…

With support from Fondation Vincent Bourque, investments help seven early-career researchers and clinicians to improve ALS patient care and deepen our understanding of the disease TORONTO, December 18, 2024 – The ALS Society of Canada (ALS Canada) and Brain…

ALS Canada is proud to recognize and celebrate Dr. Richard Robitaille, a leader in ALS research and a professor at Université de Montréal, who has received the prestigious Drs. Ayeez and Shelena Lalji & Family ALS Endowed Award for Innovative…

ALS Canada Buck-A-Puck for ALS is back! This event unites young athletes and their passion for hockey with fundraising and awareness building for amyotrophic lateral sclerosis (ALS) – a disease that affects nearly 4,000 Canadians and their families. The concept…